COBRE Center for Antimicrobial Resistance and Therapeutic Discovery

COBRE 抗菌素耐药性和治疗发现中心

基本信息

批准号：
10488596
负责人：
ERIKA M D'AGATA
金额：
$ 183.2万
依托单位：
MIRIAM HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-09-18 至 2024-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10488596
关键词：
Antibiotic Resistance Antibiotics Antimicrobial Resistance Bacterial Antibiotic Resistance Biomedical Research Biotechnology Centers of Research Excellence Cessation of life Chemotherapy-Oncologic Procedure Clinical Clinical Medicine Communicable Diseases Communities Core Facility Dedications Discipline Ensure Environment Faculty Financial Hardship Fostering Funding Generations Goals Healthcare Hospital Costs Hospitals Infection Infrastructure Institution International Intervention Investments Laboratories Laboratory Research Longevity Medical Mentors Organ Transplantation Participant Pharmaceutical Preparations Pharmacologic Substance Phase Pilot Projects Primary Health Care Program Development Research Research Personnel Resistance Resort Resources Rhode Island Services Therapeutic Training Support United States Universities Work antimicrobial drug career career development clinical practice cost design drug discovery drug resistant pathogen innovation microorganism multidisciplinary novel strategies novel therapeutic intervention novel therapeutics programs resistance mechanism success

项目摘要

Project Summary: Overall Resistance to antimicrobial therapies is a national and international crisis that threatens clinical practice from fundamental primary care to the most advanced medical interventions such as cancer chemotherapy and organ transplantation. Much of what we take for granted in clinical medicine could become too risky as microorganisms have become increasingly resistant to our newest medications and our antibiotics of last resort. Antimicrobial resistance also adds enormous costs to health care, exceeding $21 billion in the United States alone. Compounding this problem is the fact that pharmaceutical companies have largely abandoned antibiotic development programs. As an alternative to large pharmaceutical companies, academic institutions and biotech startups can step in to refill the antibiotic pipeline using novel approaches to drug discovery. The principal objective of this Phase I COBRE application is to build a unique, multi-disciplinary center of excellence to study mechanisms of antimicrobial resistance and develop therapeutic countermeasures. The long-term goal of the Center for Antimicrobial Resistance and Therapeutic Discovery (CARTD) at The Miriam Hospital of the Lifespan Hospital Group is to develop new therapies for infections caused by drug resistant pathogens. This long-term goal will be attained with shorter-term objectives of developing a new generation of junior investigators who study mechanisms of resistance, characterize new targets, and study new and existing compounds. CARTD will integrate their work with mentors and established investigators at the institution and develop core facilities to enhance research capabilities in the field of antimicrobial resistance and the discovery of new therapeutics. To achieve these objectives, the CARTD will complete the following specific aims: 1. Consolidate existing researchers into a dynamic, interactive center of excellence across The Miriam Hospital, and its academic partners in Rhode Island, including Brown University. 2. Foster the research programs and career development of junior investigators in the field of antimicrobial resistance and studies of novel therapeutic approaches. 3. Support new institutional research with pilot project funding. 4. Establish critical infrastructure with new core laboratories to facilitate cutting edge research in antimicrobial resistance and therapeutic discovery, and serve as a unique technical resources to other COBRE research programs, other institutional researchers, and investigators in the region.

项目摘要：总体对抗菌治疗的抵抗是一种国家和国际危机，威胁着临床实践对最先进的医学干预措施（例如癌症化学疗法和）的基本初级保健器官移植。我们认为，临床医学中理所当然的事情可能变得过于冒险微生物已经越来越对我们最新的药物和我们的抗生素进行抗药性采取。抗菌素耐药性还增加了巨大的卫生保健费用，统一超过210亿美元一个人。加重此问题的是制药公司在很大程度上放弃了抗生素开发计划。作为大型制药公司，学术机构的替代方案生物技术初创公司可以使用新颖的药物发现方法来介入以补充抗生素管道。这 I阶段I cobre应用的主要目标是建立一个独特的，多学科的中心卓越研究抗菌素耐药性和发展治疗对策的机制。这 Miriam抗菌素抵抗和治疗发现（CARTD）的长期目标寿命医院小组的医院是为抗药性引起的感染开发新疗法病原体。这一长期目标将以较短的目标来实现研究抵抗机制，特征新目标并研究新的和现有的初级研究人员化合物。 CARTD将将他们的工作与指导者和机构的既定调查员融合在一起，并开发核心设施，以增强抗菌耐药性领域的研究能力和发现新治疗学。为了实现这些目标，CARTD将完成以下特定目标：1。将现有的研究人员巩固到整个Miriam医院的动态互动中心，及其在罗德岛州的学术伙伴，包括布朗大学。 2。培养研究计划和抗菌抗性领域的初级研究人员的职业发展和新颖的研究治疗方法。 3。通过试点项目资金支持新的机构研究。 4。建立关键具有新的核心实验室的基础设施，以促进抗菌素耐药性和治疗性发现，并作为其他毛病研究计划的独特技术资源，其他该地区的机构研究人员和研究人员。